Saturday 14 November 2026 Daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
Market analysisEnterprise
The business of pharma
Subscribe free
Coming up
14 NovPDUFA: MYQORZO (symptomatic obstructive HCM (based on MAPLE-HCM, vs. metoprolol))14 NovPDUFA: ivonescimab (EGFR-mutated locally advanced or metastatic non-squamous NSCLC after prior EGFR TKI therapy (with chemotherapy))14 NovPDUFA: IGALMI (acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting)19 NovFDA AdComm: Microbiology Devices Panel of the Medical Devices Advisory Committee22 NovPDUFA: Deramiocel (Duchenne muscular dystrophy (DMD))27 NovPDUFA: neladalkib (ALK-positive non-small cell lung cancer)27 NovPDUFA: BBP-418 (limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9))30 NovPDUFA: povetacicept (IgA nephropathy (IgAN), accelerated approval)30 NovPDUFA: bezuclastinib (Gastrointestinal Stromal Tumors (GIST))30 NovPDUFA: Povetacicept (immunoglobulin A nephropathy (IgAN) in adults, accelerated approval)12 DecPDUFA: Quimilza (Generalized Pustular Psoriasis (GPP))12 DecPDUFA: imsidolimab (Generalized Pustular Psoriasis (GPP))14 NovPDUFA: MYQORZO (symptomatic obstructive HCM (based on MAPLE-HCM, vs. metoprolol))14 NovPDUFA: ivonescimab (EGFR-mutated locally advanced or metastatic non-squamous NSCLC after prior EGFR TKI therapy (with chemotherapy))14 NovPDUFA: IGALMI (acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting)19 NovFDA AdComm: Microbiology Devices Panel of the Medical Devices Advisory Committee22 NovPDUFA: Deramiocel (Duchenne muscular dystrophy (DMD))27 NovPDUFA: neladalkib (ALK-positive non-small cell lung cancer)27 NovPDUFA: BBP-418 (limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9))30 NovPDUFA: povetacicept (IgA nephropathy (IgAN), accelerated approval)30 NovPDUFA: bezuclastinib (Gastrointestinal Stromal Tumors (GIST))30 NovPDUFA: Povetacicept (immunoglobulin A nephropathy (IgAN) in adults, accelerated approval)12 DecPDUFA: Quimilza (Generalized Pustular Psoriasis (GPP))12 DecPDUFA: imsidolimab (Generalized Pustular Psoriasis (GPP))

Financing

IPOs, public offerings, private placements, venture rounds, debt and royalty financings, from company filings.

Financing

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Femasys reported results for the quarter ended September 30, 2026, on November 13, 2026. Total sales fell 44.5% on the timing of international FemBloc orders, while U.S. sales rose slightly to $347,039. The company closed a $30 million private placement in mid-August to build out its U.S. commercial team for the FemaSeed fertility portfolio and to fund the FemBloc pivotal trial. It also reported FDA acceptance of a modular PMA approach for FemBloc and twelve actively enrolling FINALE trial sites. Net loss was $4.56 million and cash was about $23.9 million.

13 Nov 2026 · Femasys Inc FEMY · Company news
Financing

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Mingteng International Corporation, a Cayman holding company making automotive casting molds in Wuxi, China, disclosed in its six-month period report to June 30, 2026 a June 9, 2026 registered direct offering. It agreed to sell 501,834 Class A shares at $2.00 each, plus pre-funded warrants for up to 629,170 shares, to institutional investors. The company also reported shareholder approval on May 29, 2026 of higher Class B voting rights and a par value reduction. It is not a pharma or biotech business.

13 Nov 2026 · Mingteng International Corp Inc. MTEN · Company news
Financing

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Organigram Global and Aurora Cannabis signed an arrangement agreement on November 2, 2026 (announced November 3) for Organigram to buy all Aurora shares through a court-approved plan of arrangement. Aurora holders can choose C$7.80 per share in cash, shares, or a mix, subject to proration. Funding includes a C$187.5M private placement from British American Tobacco's subsidiary and up to C$210M in ATB senior secured credit facilities. Aurora can still consider a superior proposal, which may include Curaleaf's existing hostile bid if its terms change, and both sides have termination and reverse-termination fees.

13 Nov 2026 · Organigram Global Inc. OGI · Company news
Financing

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Swiss clinical-stage biotech Windward Bio Group AG, which is developing ultra-long-acting antibodies for respiratory and dermatologic diseases, priced its initial public offering on Nov. 12, 2026. It is selling 10,294,117 common shares at $17.00 each and has granted underwriters a 30-day option for up to 1,544,117 more. Expected gross proceeds of $225.0 million include a concurrent private placement and exclude the underwriters' option.

12 Nov 2026 · Windward Bio Group AG · Company news
Financing

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq

Lichen International Limited (NASDAQ: LICN), a Chinese financial and taxation services provider rather than a pharma or biotech firm, priced a registered direct offering of 17.5 million units at $0.20 each. Each unit has one Class A share (or a pre-funded warrant) and a warrant for 4.72 shares exercisable at $0.20 for one year. Gross proceeds are about $3.5 million, with closing expected November 11, 2026 under an effective Form F-3 shelf, and Univest Securities is the sole placement agent.

12 Nov 2026 · Lichen International Ltd LICN · Company news
Financing

Tenon Medical Q3 2026 revenue up 22% to $1.4M; convertible notes repaid after $15.6M raised

Tenon Medical, maker of the SImmetry+ and Catamaran SI joint fusion systems, reported Q3 2026 results on November 12, 2026: revenue of $1.4M, gross margin of 66.3% and a net loss of $6.6M. During the quarter it raised about $15.6M gross, repaid its senior convertible notes early, regained Nasdaq compliance, and began full commercial launch of a 3D-printed lateral screw for SImmetry+. It also added eight U.S. patents and plans a full market release of the Quickstep Decorticator in Q1 2027.

12 Nov 2026 · Tenon Medical, Inc. TNON · Company news
Financing

Scribe Therapeutics posts Q3 2026 results after IPO; STX-1150 Phase 1 data due first half 2027

On November 12, 2026, Scribe Therapeutics reported Q3 results, with $174.2 million in cash after a July Nasdaq IPO and concurrent Sanofi private placement raising $155.5 million gross. Enrollment continues in the first-in-human Phase 1 trial of STX-1150, an epigenetic PCSK9-silencing therapy for LDL-C lowering, with initial data expected in the first half of 2027. The company also expanded its Sanofi collaboration to include its ELXR silencing technology and presented preclinical data on STX-1150 and STX-1200 (Lp(a)).

12 Nov 2026 · Scribe Therapeutics, Inc. SCTX · Company news
Financing

Trinity Biotech and Perceptive Credit sign fifth credit amendment waiving minimum cash covenant breaches

Trinity Biotech and its U.S. subsidiaries entered a Limited Waiver and Fifth Amendment to their credit agreement with Perceptive Credit Holdings III, LP as administrative agent, dated November 6, 2026. Lenders waived the minimum liquidity covenant for June through October 2026, after the company reported shortfalls for June, July and August. The amendment also restates the roughly $96.2 million note, and the liens securing the debt remain in place.

12 Nov 2026 · Trinity Biotech Plc TRIB · Company news
Financing

Cardiol Therapeutics files Q3 2026 MD&A, citing need for more financing as it develops heart inflammation drugs

Cardiol Therapeutics, a Canadian company developing treatments for inflammation and fibrosis in heart disease such as recurrent pericarditis, acute myocarditis and heart failure, issued its MD&A for the three and nine months ended September 30, 2026, dated November 12, 2026. The excerpt contains only the introduction and forward-looking statements and risk factors, including negative operating cash flow, a history of losses and a requirement for additional financing. It gives no financial results or clinical or regulatory updates.

12 Nov 2026 · Cardiol Therapeutics Inc. CRDL · Company news
Financing

Aptevo raises about $3.0M as warrant holders exercise at reduced $1.08 price in inducement deal

Aptevo Therapeutics, a clinical-stage immuno-oncology company, agreed with existing warrant holders on November 12, 2026 to have them exercise 2,777,778 warrants for cash at a reduced $1.08 per share, generating roughly $3.0 million in gross proceeds. In return, holders will receive new unregistered inducement warrants for up to 13,888,890 shares at $1.08, exercisable after stockholder approval and expiring five years after first exercise. Roth Capital Partners advised on the deal, and Aptevo has agreed to file a resale registration statement with the SEC.

12 Nov 2026 · Aptevo Therapeutics Inc. APVO · Company news
Financing

ADARx posts Q3 2026 results after $602.5M IPO and AbbVie placement; onvuzosiran gets FDA Fast Track for HAE

ADARx Pharmaceuticals reported Q3 2026 results on November 12, 2026, with a net loss of $28.1 million and $901.0 million in cash, which it expects to fund operations into 2030. The company closed its Nasdaq IPO and a concurrent AbbVie private placement for about $602.5 million in gross proceeds. In August 2026 the FDA granted Fast Track designation to onvuzosiran for HAE prophylaxis, and the Phase 3 STOP-HAE trial is expected to read out by the end of 2027. Three Phase 2 trials of agazisiran in complement-mediated diseases are ongoing.

12 Nov 2026 · ADARx Pharmaceuticals, Inc. ADRX · Company news
Financing

NorthStar Earth & Space closes Viking SPAC merger, lists on NYSE American with US$30M PIPE

NorthStar Earth & Space, a space-based situational awareness data analytics company, finished its business combination with Viking Acquisition Corp. I on October 1, 2026. The deal came with a US$30.0 million PIPE and a listing of its common shares and warrants on NYSE American. The MD&A, filed on Form 6-K, also flags limited cash, about 96% redemption of Viking public shares, and a Spire arbitration award. This is not a pharma or biotech item.

12 Nov 2026 · NorthStar Earth & Space Enterprises, Inc. NSTR · Company news
Financing

Hydrofarm regains Nasdaq equity compliance after eliminating $109 million term loan

Hydrofarm Holdings Group, a controlled-environment agriculture supplier and not a pharma company, said Nasdaq confirmed by letter dated November 9, 2026 that it again meets the $2.5 million minimum stockholders' equity rule. The confirmation followed the October 27 termination of its $109 million term loan, a registered direct offering and a concurrent private placement. The company still has to meet the minimum bid price requirement and remains under a mandatory panel monitor.

12 Nov 2026 · Hydrofarm Holdings Group, Inc. HYFM · Company news
Financing

Innoviz details $30M registered direct offering, ATM sales and $3.5M defense orders in 6-K update

Innoviz Technologies, an automotive LiDAR supplier, filed a Form 6-K with its management discussion covering recent developments. The company closed a registered direct offering of about 66.7 million shares at $0.45 on July 29, 2026, netting about $27.6 million, and sold shares under its ATM program for about $8.0 million. It also reported initial defense orders of about $3.5 million, a new board chair, and a Nasdaq minimum bid price deficiency notice. The company is not a pharma/biotech business, so the filing carries no drug-specific regulatory content.

12 Nov 2026 · Innoviz Technologies Ltd. INVZ · Company news
Financing

Starling Oncology investor deck: FY26 revenue guided to $650-660M after OrbiMed refinancing and rebrand

Starling Oncology, a value-based oncology care and benefits management company now trading on Nasdaq as STLN, issued an investor presentation dated November 2026. It cites Q3 2026 revenue of $170M (up 24% year over year), FY26 revenue guidance of $650-660M and Adjusted EBITDA of $4-6M. It also covers repayment of an $86M Deerfield note through an OrbiMed refinancing, 2.2M+ value-based care lives, and growth in capitated contracts outside California.

12 Nov 2026 · Starling Oncology, Inc. DFPH · Company news
Financing

Lisata Therapeutics closes Marea Therapeutics merger and $225M private placement, with pro forma financials

Lisata Therapeutics completed its acquisition of Marea Therapeutics on September 17, 2026, issuing common stock and Series C Non-Voting Convertible Preferred Stock to Marea holders. A concurrent private placement of Series C preferred to institutional investors closed September 18 for about $225.0 million gross. Following stockholder approval and conversion, former Marea holders are expected to own about 59.5% of the combined company, PIPE investors about 38.1% and legacy Lisata holders about 2.4%; the filing presents unaudited pro forma combined financials.

12 Nov 2026 · Lisata Therapeutics, Inc. LSTA · Company news
Financing

Addex spin-out Neurosterix closes $105M Series B to fund Phase 2 of schizophrenia drug NTX-253

Neurosterix, the 2024 spin-out of Addex Therapeutics, closed a $105 million Series B round from life science investors, announced on November 11, 2026. Proceeds will mainly fund Phase 2 development of NTX-253, an oral M4 positive allosteric modulator for schizophrenia, and the company's wider neuropsychiatric pipeline. Addex did not take part, and its stake is now 8.5%, valued at $18.6 million.

12 Nov 2026 · Addex Therapeutics Ltd. ADXN · Company news
Financing

Eupraxia Pharmaceuticals sets up at-the-market share sales program with Jefferies under US$300M shelf

Eupraxia Pharmaceuticals entered an Open Market Sale Agreement dated November 10, 2026 with Jefferies LLC and Jefferies Securities, Inc. It allows the company to issue and sell common shares from time to time on Nasdaq and the TSX, at a 3% selling commission. The program is drawn from the company's Canadian short form base shelf prospectus of up to US$300 million, with the British Columbia Securities Commission as principal regulator.

10 Nov 2026 · Eupraxia Pharmaceuticals Inc. EPRX · Company news
Financing

Aptera Motors prices $6M registered direct offering with concurrent warrant private placement

On November 10, 2026, Aptera Motors, a solar electric vehicle developer, agreed with institutional investors to sell about 3.43 million Class B shares at $1.75 each in a registered direct offering. A concurrent private placement adds warrants for the same number of shares at a $2.05 exercise price, exercisable only after stockholder approval. Gross proceeds of about $6 million are earmarked for vehicle validation, manufacturing readiness and production planning, with closing expected around November 11, 2026. The company is not a pharma business, so the item is of limited relevance to life-sciences readers.

10 Nov 2026 · Aptera Motors Corp SEV · Company news
Financing

NextCure's Avere merger financing rises to about $820M as SEC clears S-4 and vote is set for Dec 9

On November 10, 2026, NextCure reported Q3 results and said the financing for its proposed merger with Avere Therapeutics, developer of oral IL-23 therapy AVR-001, had grown to roughly $820 million. The SEC declared the S-4 effective on November 6, and stockholders vote on December 9, 2026. NextCure also handed the LNCB74 IND to LigaChem, restructured, and ended its SIM0505 study treatment, leaving $8.7 million in cash.

10 Nov 2026 · NextCure, Inc. NXTC · Company news
Financing

Gossamer Bio files first NDA for seralutinib in PAH; $125M more in financing tied to FDA acceptance

Gossamer Bio reported Q3 2026 results on November 10, 2026, and said it submitted its first New Drug Application to the U.S. FDA in September 2026 for inhaled seralutinib in pulmonary arterial hypertension. The FDA has yet to decide whether to accept the filing. Acceptance in 2026 would unlock up to about $125 million of committed private placement capital. The company ended the quarter with $51.2 million in cash and securities after reacquiring worldwide rights from Chiesi and completing a 1-for-80 reverse split.

10 Nov 2026 · Gossamer Bio, Inc. GOSS · Company news
Financing

MaxCyte to buy Akron Bio for $151.8M and secures up to $75M MidCap credit facility

MaxCyte (NASDAQ: MXCT) announced on November 10, 2026 a definitive agreement to acquire Akron BioProducts, a supplier of GMP-grade reagents and ancillary materials for cell therapy manufacturing, from Arcline Investment Management. Consideration is $105M in cash, about 20.6M MaxCyte shares and $20M in deferred payments, with closing expected before the end of 2026 and no stockholder approval needed. MaxCyte also arranged a MidCap Financial facility of up to $75M, and the combined company's products are referenced in drug master files supporting five approved therapies and over 100 clinical programs.

10 Nov 2026 · Maxcyte, Inc. MXCT · Company news
Financing

Attovia posts positive 12-week Phase 1b ATTO-1310 itch data, plans 2027 Phase 2 trials; IPO lifts cash to $395.9M

On November 9, 2026, Attovia Therapeutics reported Q3 results and a corporate update. It announced positive 12-week Phase 1b topline data for the IL-31 antibody ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. The ATTUNE-CPUO Phase 2 design has been aligned with the FDA, and Phase 2 trials are expected to start in 1H 2027. Cash of about $395.9 million, boosted by an August 2026 IPO, is expected to fund operations into 2030.

09 Nov 2026 · Attovia Therapeutics, Inc. ATTO · Company news
Financing

Atea's BEM/RZR meets Phase 3 C-BEYOND endpoints in HCV; company secures up to $200M Hercules credit facility

Atea Pharmaceuticals reported Q3 2026 results on November 9, 2026. Its Phase 3 C-BEYOND trial showed bemnifosbuvir/ruzasvir was non-inferior to Epclusa in hepatitis C (SVR 93.91% vs 94.75%), with C-FORWARD data expected in early 2027 and an FDA NDA targeted for mid-2027. Atea also signed a credit facility with Hercules Capital for up to $200 million, drawing $65 million at closing, and continues Phase 1 development of AT-587 for chronic hepatitis E.

09 Nov 2026 · Atea Pharmaceuticals, Inc. AVIR · Company news
Financing

Jasper Therapeutics reports 68.94% of warrants tendered in $0.324-per-warrant buyback offer

Jasper Therapeutics (Nasdaq: JSPR) announced on November 9, 2026 the results of its cash tender offer for warrants issued in its September 2025 underwritten public offering, which expired November 7, 2026. Holders tendered 8,510,658 warrants, about 68.94% of those outstanding, and the company expects to pay roughly $2.76 million at $0.324 per warrant. The offer was made under a Schedule TO filed with the SEC on October 7, 2026.

09 Nov 2026 · Jasper Therapeutics, Inc. JSPR · Company news
Financing

Mentari Therapeutics completes InMed merger and $490M private placements; begins Nasdaq trading as MTRI

On November 9, 2026, Mentari Therapeutics closed its merger with InMed Pharmaceuticals and began trading on the Nasdaq Capital Market under the ticker MTRI. Just before closing, it completed private placements worth about $490 million in gross proceeds, which it says funds operations into 2029. The company is developing PACAP-targeting migraine-prevention antibodies: MT-001 is in Phase 1 with initial data expected mid-2027, and a regulatory filing for the bispecific MT-002 is planned for Q1 2027.

09 Nov 2026 · InMed Pharmaceuticals Inc. INM · Company news
Financing

Abeona buys Ellodi's EoE drug ABO-801 for $20M in stock and lines up $30M private placement

On November 9, 2026, Abeona Therapeutics announced it acquired APT-1011, renamed ABO-801, from Ellodi Pharmaceuticals. ABO-801 is a once-daily oral fluticasone propionate tablet for eosinophilic esophagitis with FDA Orphan Drug designation. The deal involves no upfront cash, and Abeona also signed a $30 million private placement; it plans to start a new Phase 3 study in Q2 2027, after two earlier Phase 3 studies missed their co-primary symptom endpoint.

09 Nov 2026 · Abeona Therapeutics Inc. ABEO · Company news
Older →